# SPECIALTY GUIDELINE MANAGEMENT

# FIBRYGA (fibrinogen [human])

### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

## FDA-Approved Indication

Fibryga is indicated in adults and adolescents with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia, for the treatment of acute bleeding episodes.

Fibryga is not indicated for dysfibrinogenemia.

All other indications are considered experimental/investigational and not medically necessary.

### **II. CRITERIA FOR INITIAL APPROVAL**

### **Fibrinogen Deficiency**

Authorization of 1 month may be granted for treatment of acute bleeding episodes in members with a diagnosis of congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

### **III. CONTINUATION OF THERAPY**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

#### IV. REFERENCES

- 1. Fibryga [package insert]. Hoboken, NJ: Octapharma USA, Inc.; September 2017.
- 2. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders. Revised August 2020. MASAC Document #263. https://www.hemophilia.org/sites/default/files/document/files/263\_treatment.pdf. Accessed October 14, 2020.

Fibryga 2989-A SGM P2021.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2020 CVS Caremark. All rights reserved.

**♥CVS** caremark<sup>™</sup>



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of